MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Topography of cholinergic vulnerability correlates of PIGD motor deficits in DLB and PSP: A [18F]-FEOBV PET study

    P. Kanel, T. Brown, S. Roytman, J. Barr, C C. Spears, N. Bohnen (Ann Arbor, USA)

    Objective: To understand the relationship between cholinergic vulnerability and Postural Instability and Gait Disturbances (PIGD) motor features in dementia with Lewy bodies (DLB), and progressive…
  • 2023 International Congress

    Depression in Parkinson’s disease is associated with subcortical neurodegeneration and increased risk of all-cause mortality and dementia

    J. Badenoch, A. Paris, B. Jacobs, A. Noyce, C. Marshall, S. Waters (London, United Kingdom)

    Objective: To evaluate the temporality, neuroanatomical correlates and prognostic significance of depression in PD using a large population cohort. Background: Depression may be an important…
  • 2023 International Congress

    Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials

    K. Chaudhuri, M. Bouchard, E. Freire-Alvarez, R. Pahwa, L. Bergmann, R. Gupta, P. Kukreja, M. Shah, S. Isaacson (London, United Kingdom)

    Objective: To assess nocturia over time and its correlation with quality of life (QoL) in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…
  • 2023 International Congress

    Instability after MRIg-FUS thalamotomy: why does it appear?

    A. Fernandez Revuelta, C. Ribacoba Díaz, J. Porta Etessam, C. Pérez García, M. Yus, E. López Valdés, R. García-Ramos (Madrid, Spain)

    Objective: To know the semiological characteristics and physiopathology of instability after thalamotomy with Magnetic Resonance image guided focused ultrasound thalamotomy (MRIg-FUS). Background: Gait instability is…
  • 2023 International Congress

    IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: a real-life study: 4-year interim results

    B. Bergmans, N. Winter, V. Schotte, N. Sys, L. Delameilleure, E. van Massenhove, H. Couckuyt, M. van Zandijcke (Bruges, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea. Background: Sialorrhea is frequently a…
  • 2023 International Congress

    Understanding patient perceptions of advanced Parkinson’s disease (aPD) treatments

    J. Domingos, R. Pahwa, A. Antonini, I. Malaty, S. Lindvall, F. de Renzis, C. Yan, K. Pantiri, N. Touba, E. Evans, A. Alobaidi, A. Shewale, M. Shah, P. Kukreja, J. Zamudio, K. Chaudhuri (Orpington Kent, United Kingdom)

    Objective: To explore patients’ perceptions of treatment options for aPD and treatment decision considerations. Background: As PD advances, some people with Parkinson’s (PwP) on oral…
  • 2023 International Congress

    local field potential differences in stn subregion during performance of a conflict task in humans with parkinson’s disease

    J. Bowersock, J. Neimat, A. Alhourani, T. Stewart, S. Wylie, N. van Wouwe (Flagstaff, USA)

    Objective: Examine dorsal and ventral STN subregion's roles in motor conflict with intraoperative recordings during the implantation of a DBS device in Parkinson’s disease (PD)…
  • 2023 International Congress

    Exome-wide contribution of ultra-rare variants to the genetic architecture of Parkinson’s disease and Cutaneous Malignant Melanoma

    B. Bustos, T. Krainc, Z. Gan-Or, C. Cruchaga, B. Benitez, T. Bishop, H. Morris, S. Lubbe (Chicago, USA)

    Objective: To analyze the UKBiobank cohorts of Parkinson’s disease (PD) and Cutaneous Malignant Melanoma to uncover shared genetic factors explained by ultra-rare damaging coding variants…
  • 2023 International Congress

    Deep brain stimulation impacts functional brain connectivity in Parkinson’s disease.

    R. Jech, F. Ruzicka, D. Kiakou, A. Lasica, P. Filip, K. Burdova, D. Urgosik, K. Mueller (Prague, Czech Republic)

    Objective: Deep-brain stimulation (DBS) became a successful method to treat Parkinson’s disease (PD), particularly with stimulating the subthalamic nucleus (STN-DBS), although the precise mechanisms mediating…
  • 2023 International Congress

    Putting the patient’s voice at the venter: Tracking the impact of botulinum neurotoxin therapy for movement disorders using patient-reported outcomes

    S. Samadzadeh, V. Koska, J. Waskönig, PJ. Jouvenal, SGM. Meuth, HH. Hefter, PA. Albrecht (Düsseldorf, Germany)

    Objective: To investigate how patient reported outcomes (PROs) perform to document the effects of a botulinum neurotoxin (BONT) treatment of movement disorders in the clinical…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley